Henrik Edgren, Medisapiens, HARMONY Partner, explains how the ...
Interview with Dr. Guillermo Sanz, Co-Chair HARMONY Alliance: ...
Ken Mills of Queens University Belfast, HARMONY Associated
New IMI project launched: EHDEN, European Health Data & Evidence ...
Maurille Feudjo Tepie of HARMONY Partner AMGEN, addressing BigData ...
Jonathan Pearce, Lymphoma Coalition, about the importance of ...
HARMONY Partner Celgene facilitated an awareness meeting explaining ...
Special report Financial Times: EU’s Innovative Medicines ...
Ana Heredia Casanoves, GMV explains the HARMONY Data Platform ...
Prof Andrea Manca, University of York, elaborates on
Blog: 'In data we trust, if patients are involved', by HARMONY ...
HARMONY & ASH2018: 60th Annual Meeting of the American Society ...
HARMONY young talent presenting at the IMI 10th Anniversary
HARMONY partners attending SEHH, the 60th National Congress
Medical University of Vienna representing HARMONY at
Prof Natacha Bolaños, Lymphoma Coalition Europe/HARMONY ...
General Assembly 2018: Discussing topics important for all
BD4BO organizes workshop at the European Health Forum Gastein ...
UNITO presents HARMONY poster at the 10th IMI Anniversary Scientific ...
New IMI Paper highlights importance of global data standards. ...
Watch the video of Jan Geissler, LeukaNet, explaining the potential ...
Listen to the interview with Prof Ghia, European Research
HARMONY Partners Leukanet and EORTC participated in ECCO2018 ...
HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).